Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

NCT06691217 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Vascular Inflammation
ASCVD
ASCVD Management

Interventions

DRUG: CANAKINUMAB (ILARIS®)
DRUG: Saline (NaCl 0,9 %) (placebo)

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]